Royal Bank of Canada
LUCD icon

Royal Bank of Canada’s Lucid Diagnostics LUCD Stock Holding History

Royal Bank of Canada’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26K Buy
24,437
+16,530
+209% +$17.8K ﹤0.01% 6169
2026
Q1 		$9K Sell
7,907
-2,433
-24% -$3.1K ﹤0.01% 6210
2025
Q4 		$11K Buy
10,340
+5,247
+103% +$5.87K ﹤0.01% 6365
2025
Q3 		$5K Buy
5,093
+2,594
+104% +$2.83K ﹤0.01% 6702
2025
Q2 		$2K Buy
+2,499
New +$3.23K ﹤0.01% 6805
2024
Q3 		– Sell
-196
Closed – – 7177
2024
Q2 		$0 Buy
196
+107
+120% +$91 ﹤0.01% 7334
2024
Q1 		$0 Sell
89
-109
-55% -$141 ﹤0.01% 7337
2023
Q4 		$0 Buy
+198
New +$261 ﹤0.01% 7379
2023
Q3 		– Sell
-95
Closed – – 7354
2023
Q2 		$0 Buy
+95
New +$143 ﹤0.01% 7474
2022
Q2 		– Sell
-910
Closed -$3K – 7565
2022
Q1 		$3K Sell
910
-764
-46% -$2.79K ﹤0.01% 7389
2021
Q4 		$9K Buy
+1,674
New +$13.6K ﹤0.01% 7083

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Royal Bank of Canada's LUCD Position: Q2 2026 in Review

Royal Bank of Canada increased its Lucid Diagnostics (LUCD) stake by 209% in Q2 2026, buying an estimated $17.8K and bringing the position to 24,437 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #6169.

Royal Bank of Canada first reported a position in LUCD in Q4 2021 and has held it in 11 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Royal Bank of Canada held 24,437 shares of Lucid Diagnostics worth $26K as of Q2 2026.
  • Royal Bank of Canada bought 16,530 Lucid Diagnostics shares in Q2 2026, an estimated $17.8K.
  • Lucid Diagnostics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6169 holding.
  • Royal Bank of Canada first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 11 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.